The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
The Korea Times
amn_close.png
amn_bl.png
National
  • Politics
  • Foreign Affairs
  • Multicultural Community
  • Defense
  • Environment & Animals
  • Law & Crime
  • Society
  • Health & Science
amn_bl.png
Business
  • Tech
  • Bio
  • Companies
amn_bl.png
Finance
  • Companies
  • Economy
  • Markets
  • Cryptocurrency
amn_bl.png
Opinion
  • Editorial
  • Columns
  • Thoughts of the Times
  • Cartoon
  • Today in History
  • Blogs
  • Tribune Service
  • Blondie & Garfield
  • Letter to President
  • Letter to the Editor
amn_bl.png
Lifestyle
  • Travel & Food
  • Trends
  • People & Events
  • Books
  • Around Town
  • Fortune Telling
amn_bl.png
Entertainment & Arts
  • K-pop
  • Films
  • Shows & Dramas
  • Music
  • Theater & Others
amn_bl.png
Sports
amn_bl.png
World
  • SCMP
  • Asia
amn_bl.png
Video
  • Korean Storytellers
  • POPKORN
  • Culture
  • People
  • News
amn_bl.png
Photos
  • Photo News
  • Darkroom
amn_NK.png amn_DR.png amn_LK.png amn_LE.png
  • bt_fb_on_2022.svgbt_fb_over_2022.svg
  • bt_twitter_on_2022.svgbt_twitter_over_2022.svg
  • bt_youtube_on_2022.svgbt_youtube_over_2022.svg
  • bt_instagram_on_2022.svgbt_instagram_over_2022.svg
  • Login
  • Register
  • Login
  • Register
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
  • 1

    Revised Japanese textbooks distort wartime forced labor, catching Korea off guard

  • 3

    Actor Yoo Ah-in once again apologizes for alleged drug use

  • 5

    Korea to ease entry rules to boost tourism, domestic spending

  • 7

    Gold price nears all-time high amid financial jitters

  • 9

    Ramsar wetland in Han River cleaned up for protected birdlife

  • 11

    North Korea unveils tactical nuclear warheads

  • 13

    BTS' Jimin tops Spotify's global chart with 'Like Crazy'

  • 15

    Over 1,000 financially vulnerable Koreans apply for new emergency gov't loans

  • 17

    Suspect identified in Nashville school shooting that killed 3 children, 3 staff

  • 19

    Ra Mi-ran, Lee Re to lead fantasy drama 'The Mysterious Candy Store'

  • 2

    Chun Doo-hwan's grandson apprehended at Incheon Int'l Airport over drug use

  • 4

    Clock ticks for China's massive repatriation of N. Korean defectors

  • 6

    'My ID is Gangnam Beauty' to be adapted into live action series in Thailand

  • 8

    BMW launches new XM

  • 10

    Civic groups in Gwangju await meeting with Chun Doo-hwan's grandson

  • 12

    CJ CheilJedang sees chicken as next big seller after frozen dumpling

  • 14

    From IVE to NCT DOJAEJUNG, K-pop hotshots brace for April chart race

  • 16

    2024 budget to focus on tackling low birthrate

  • 18

    INTERVIEWChoi Min-sik, Lee Dong-hwi on creating Korean-style noir with 'Big Bet'

  • 20

    Samsung Pay partners with Hana Financial to issue student IDs

Close scrollclosebutton

Close for 24 hours

Open
  • The Korea Times
  • search
  • all menu
  • Login
  • Subscribe
  • Photos
  • Video
  • World
  • Sports
  • Opinion
  • Entertainment & Art
  • Lifestyle
  • Finance
  • Business
  • National
  • North Korea
Business
  • Tech
  • Bio
  • Companies
Thu, March 30, 2023 | 12:05
Bio
HLB's US affiliate Verismo sets up Asia headquarters in Korea
Posted : 2022-02-15 17:16
Updated : 2022-02-15 17:48
Baek Byung-yeul
Print PreviewPrint Preview
Font Size UpFont Size Up
Font Size DownFont Size Down
  • facebook
  • twitter
  • kakaolink
  • whatsapp
  • reddit
  • mailto
  • link
HLB Group Chairman Jin Yang-gon, right, poses with Verismo Asia CEO Byung-girl Lee, second from left, and Verismo Therapeutics CEO Bryan Kim, second from right, Feb. 14. Courtesy of HLB
HLB Group Chairman Jin Yang-gon, right, poses with Verismo Asia CEO Byung-girl Lee, second from left, and Verismo Therapeutics CEO Bryan Kim, second from right, Feb. 14. Courtesy of HLB

By Baek Byung-yeul

Verismo Therapeutics, a new drug development company based in the U.S., established its Asia branch in Korea as part of its plan to facilitate clinical trials of its anti-cancer drug platform in the Asia region, the Korean biotech company HLB said Tuesday.

HLB Group is a major shareholder of Verismo Therapeutics, as HLB Pharmaceutical and HLB invested $10 million and $5 million, respectively, in 2021 to acquire a 30 percent stake in the U.S.-based company.

Verismo is a biotech company established by a University of Pennsylvania research team. The team led the development of Novartis' Kymriah, the world's first chimeric antigen receptor-T (CAR-T) treatment for hematological cancers approved by the U.S. Food and Drug Administration.

Verismo has its own SynKIR platform that can express a multi-chain receptor similar to the receptor structure mainly expressed in natural killer (NK) cells, which kills cancerous and virus-infected cells in the body. Among Verismo's many pipelines in development, SynKIR-110, the first pipeline for indications for pancreatic cancer, mesothelioma and ovarian cancer, is currently being prepared for an investigational new drug (IND) for phase 1 clinical trials in the U.S.

Its Asia branch will conduct development and clinical trials of the pipelines for Korea, Japan, China and others, by licensing SynKIR from Verismo. In addition, the company plans to expand its business areas by developing various other CAR T-cell therapies that can be specialized for the region's needs, by forming joint ventures with strategic biopharmaceutical partners in each country.

The Asia branch is on its way to establishing a partnership with a major medical center in Korea where it will not only conduct its first human clinical trials but also establish a manufacturing facility for T-cell products.

"Verismo Asia is working to be a leading CAR T-cell company in Asia by equipping various CAR T oncology pipelines, starting with the pancreatic cancer clinical trial of SynKIR-110 in Korea," Byung-girl Lee, CEO of Verismo Asia, said in a statement. "We are working to address key issues such as building a manufacturing facility and securing clinical hospitals."


Emailbaekby@koreatimes.co.kr Article ListMore articles by this reporter
 
Top 10 Stories
1Korea to ease entry rules to boost tourism, domestic spending Korea to ease entry rules to boost tourism, domestic spending
2Korea moves to shorten COVID-19 isolation period to 5 days Korea moves to shorten COVID-19 isolation period to 5 days
3[INTERVIEW] Can art become stable investment source? INTERVIEWCan art become stable investment source?
4Will dismantling oligopoly result in successful bank industry reform? Will dismantling oligopoly result in successful bank industry reform?
5Fintech, lifestyle products can help Korea grow trade ties with Hong Kong: city's trade promotion chief in Korea Fintech, lifestyle products can help Korea grow trade ties with Hong Kong: city's trade promotion chief in Korea
6Generation Z entrepreneurs turn oyster shells into trendy dish soapGeneration Z entrepreneurs turn oyster shells into trendy dish soap
7Celltrion chairman vows to develop new drugs, initiate M&As Celltrion chairman vows to develop new drugs, initiate M&As
8Terraform Labs co-founder's extradition could be delayed more than 1 month Terraform Labs co-founder's extradition could be delayed more than 1 month
9Ex-journalist to lead NK defector support foundation Ex-journalist to lead NK defector support foundation
10Seoul participates in Asia's biggest smart city expo in Taipei Seoul participates in Asia's biggest smart city expo in Taipei
Top 5 Entertainment News
1'My ID is Gangnam Beauty' to be adapted into live action series in Thailand 'My ID is Gangnam Beauty' to be adapted into live action series in Thailand
2From IVE to NCT DOJAEJUNG, K-pop hotshots brace for April chart race From IVE to NCT DOJAEJUNG, K-pop hotshots brace for April chart race
3[INTERVIEW] Choi Min-sik, Lee Dong-hwi on creating Korean-style noir with 'Big Bet' INTERVIEWChoi Min-sik, Lee Dong-hwi on creating Korean-style noir with 'Big Bet'
4Ra Mi-ran, Lee Re to lead fantasy drama 'The Mysterious Candy Store' Ra Mi-ran, Lee Re to lead fantasy drama 'The Mysterious Candy Store'
5[INTERVIEW] Ahn Jae-hong on playing underdog basketball coach in 'Rebound' INTERVIEWAhn Jae-hong on playing underdog basketball coach in 'Rebound'
DARKROOM
  • Turkey-Syria earthquake

    Turkey-Syria earthquake

  • Nepal plane crash

    Nepal plane crash

  • Brazil capital uprising

    Brazil capital uprising

  • Happy New Year 2023

    Happy New Year 2023

  • World Cup 2022 Final - Argentina vs France

    World Cup 2022 Final - Argentina vs France

CEO & Publisher : Oh Young-jin
Digital News Email : webmaster@koreatimes.co.kr
Tel : 02-724-2114
Online newspaper registration No : 서울,아52844
Date of registration : 2020.02.05
Masthead : The Korea Times
Copyright © koreatimes.co.kr. All rights reserved.
  • About Us
  • Introduction
  • History
  • Contact Us
  • Products & Services
  • Subscribe
  • E-paper
  • RSS Service
  • Content Sales
  • Site Map
  • Policy
  • Code of Ethics
  • Ombudsman
  • Privacy Statement
  • Terms of Service
  • Copyright Policy
  • Family Site
  • Hankook Ilbo
  • Dongwha Group